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Keloids are benign fibroproliferative tumors of the skin which commonly occur after injury mainly in darker skinned patients.
Medical treatment is fraught with high recurrence rates mainly because of an incomplete understanding of the biological
mechanisms that lead to keloids. The purpose of this project was to examine keloid pathogenesis from the epigenome perspective of
DNA methylation. Genome-wide profiling used the Infinium HumanMethylation450 BeadChip to interrogate DNA from 6 fresh
keloid and 6 normal skin samples from 12 anonymous donors. A 3-tiered approach was used to call out genes most differentially
methylated between keloid and normal. When compared to normal, of the 685 differentially methylated CpGs at Tier 3, 510 were
hypomethylated and 175 were hypermethylated with 190 CpGs in promoter and 495 in nonpromoter regions. The 190 promoter
region CpGs corresponded to 152 genes: 96 (63%) were hypomethylated and 56 (37%) hypermethylated. This exploratory genomewide scan of the keloid methylome highlights a predominance of hypomethylated genomic landscapes, favoring nonpromoter
regions. DNA methylation, as an additional mechanism for gene regulation in keloid pathogenesis, holds potential for novel
treatments that reverse deleterious epigenetic changes. As an alternative mechanism for regulating genes, epigenetics may explain
why gene mutations alone do not provide definitive mechanisms for keloid formation.

1. Introduction
Keloids are benign fibroproliferative tumors that are unique
to humans [1]. The exact mechanism of keloid formation is
unknown. There is up to a 20% incidence in Blacks, Asians,
and Hispanics [2–7]. Dysregulations of genes important in
apoptosis, extracellular matrix formation, and immunity have
been described in the pathogenesis of keloids [8, 9]. However,
no clear-cut genetic alterations or involvement have emerged
for keloids. Clinical outcomes for the treatment of keloids
are disappointing. Surgical excision of keloids has a 50–100%
recurrence [10]. Furthermore, the recurrence rate of surgical
excision combined with adjuvant therapy, such as steroid
injection, silicone therapy, pressure therapy, radiotherapy,
and anticancer drugs, remains high with up to 50% reported
in the literature [3]. The failure of adjuvant therapies, despite
being based on current clinical, histological, or molecular

observations, underscores the heterogeneity of keloid formation and the need for insight into the molecular pathogenesis
of keloids to account for its complexity.
Keloid molecular studies have focused primarily on
genetic mechanisms. These approaches have yielded some
tangible results, albeit with large gaps in our understanding
of keloid pathogenesis [11]. Epigenetics is the study of gene
alteration that occurs without altering the DNA sequence.
For example, DNA hypermethylation is used to turn off
genes in normal human development, such as imprinting and
X chromosomal inactivation [12–14]. Aberrant methylation,
the addition of a methyl group (CH3 ) at cytosine bases
of DNA (hypermethylation), or removal (hypomethylation)
can lead to genomic instability and tumorigenesis [15].
Hypermethylation in the cytosine-phosphodiester bondguanine (CpG) islands of a gene’s promoter region can result
in gene inactivation, whereas hypomethylation can cause
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gene activation [16–18]. Recent evidence suggests that DNA
methylation changes may underlie numerous complex traits
and diseases [19–21]. As an alternative mechanism for regulating genes, epigenetics may explain why gene mutations alone
do not provide definitive mechanisms for keloid formation.
Historically, the molecular pathogenesis of disease has
been teased out one gene at a time. The development of
several new high-throughput methods for the analysis of
DNA, mRNA, and proteins within a cell has permitted
a more detailed molecular characterization of the cancer
genome. Given the tumor-like behavior of keloids, it is
plausible that similar techniques could be applied to the
study of keloid pathogenesis. Studies have shown downregulation of apoptotic genes in keloid tissue, including those
that both promote and inhibit apoptosis [22]. Furthermore,
immunohistochemistry data indicate upregulation of tumor
suppressor genes, such as p53, and protooncogenes, such
as bcl2 [16]. However, these methods have not adequately
addressed the complexity of the disease. A combination of
genomic, epigenomic, and environmental factors more likely
underscores the pathogenesis of complex diseases such as
keloids.
The objective of this study was to gain insight into
keloid pathogenesis from the epigenome perspective of DNA
methylation. This study used a global discovery strategy
to characterize the keloid methylome and identify keloidspecific methylated markers to aid in the understanding of
the disease.

2. Materials and Methods
Discarded anonymous human keloid and normal skin tissue
was obtained from patients via a protocol approved by the
institutional review board. Six fresh keloid and 6 normal skin
samples from the head and neck area from 12 anonymous
donors were obtained for the study cohort. Normal skin
was chosen as a control because keloids form from normal
skin. Genome-wide profiling was done using the Infinium
HumanMethylation450 BeadChip platform.
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performed at the Applied Genomics Technology Center,
Wayne State University, Detroit, MI. DNA was extracted
according to the manufacturer’s protocol (Qiagen Inc.,
Chatsworth, CA). Following DNA quality checks of original DNA quality, quantification, and bisulfite conversion,
4 𝜇L of bisulfite-converted DNA was used for hybridization
according to Illumina Infinium methylation protocols. Data
were normalized using the Controls Normalization method
(Illumina, San Diego, CA). The methylation score for each
CpG was represented as a beta (𝛽) value according to the
fluorescent intensity ratio. Every 𝛽-value in the Infinium
HumanMethylated450 BeadChip platform was accompanied
by a detection 𝑃 value. 𝛽-values may take any value between
0 (nonmethylated) and 1 (completely methylated) and were
determined using the Genome Studio V2009.2, Methylation
Module Version 1.5.5., Version 3.2 (Illumina, San Diego, CA).
Probes were discarded if this detection 𝑃 value was more than
0.05. The only corrections that were made to the data were
background subtraction and normalization.
The resulting 𝛽-values were exported into Microsoft
Excel, JMP, and SAS (SAS Institute, Cary, NC) for data
analysis. All genome-wide comparisons were corrected for
multiple comparisons using the method of Benjamini and
Hochberg [24].
2.3. Data Analysis. To identify differentially methylated
keloid-specific genes, a three-tiered approach was developed [25]. Our goal for a 3-Tier system was to provide a
framework to increase statistical rigor in the detection of
biologically relevant methylation markers. The latter achieves
two outcomes: (1) exclusion of CpGs likely increases the risk
of false discoveries and (2) serves as a strategy to reduce
the number of genes/CpGs for confirmation especially for
study cohorts with DNA and RNA sources challenged by
formalin-fixation or meager amounts of tissue availability
for molecular characterization [25]. In Tier 1, we computed
adjusted false discovery rate values for all CpGs and required
this to be 0.05 or lower. In Tier 2, in order to heuristically
move from Tier 1, we filtered the Tier 1 CpGs to include
only those with a twofold change (ratio ≥ 2.0 or ≤ 0.5).
Tier 3 added another CpG filter to include only those with
an absolute difference between the mean 𝛽 of ≥0.2. A CpG
was classified as associated with a promoter region if the
Illumina annotation for any of the associated gene isoforms
was designated as translation start site (TSS) 200, TSS1500,
5 untranslated region (UTR), or 1st exon. Nonpromoter
regions included gene body, 3 UTR, and others (intergenic).
The addition of Tier 2 and 3 criteria was intended to downsize
the number of CpGs/genes whose differential methylation
likely represented the most robust of biologically significance.
This study focused on promoter region CpGs; therefore, only
Tier 3 CpGs were correlated for associated genes.

2.1. Distribution and Classification of the 450,000 Cytosine
Sites in the Human Genome. The Infinium HumanMethylation450 BeadChip platform provides coverage of 99% of Reference Sequence genes. The Reference Sequence collection
aims to provide a comprehensive, integrated, nonredundant,
well-annotated set of sequences, including genomic DNA,
transcripts, and proteins [23]. The 450K DNA methylation
array includes 485,764 cytosine positions in the human
genome. From these cytosine sites, 482,421 positions (99.3%)
are CpG dinucleotides, while 3,343 sites (0.7%) correspond to
non-CpG targets. The interrogated CpG sites are distributed
among all human 22 autosomal and 1 sex chromosome pairs
[23]. From the functional genome distribution standpoint,
200,339 CpGs (41%) are located in proximal promoters and
became the focus of analyses for this study.

3. Results

2.2. Processing Samples for the Infinium HumanMethylation450. The Infinium HumanMethylation450 assays were

With respect to this sample set, >99.7% of the 485,577
Illumina probes had detection 𝑃 values under 0.05. Of the
485,577 cytosine positions, when compared to normal, Tier
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Figure 1: (a) Methylation status of the 685 differentially methylated CpGs (cytosine-phosphodiester bond-guanine) at Tier 3 (26%
hypermethylated, 74% hypomethylated). (b) 685-CpG distributions in promoter versus nonpromoter (28% promoter, 72% nonpromoter). (c)
Methylation status of 190 promoter CpGs (33% hypermethylated, 67% hypomethylated). (d) 190-CpG distribution in promoter regions (41%
5 UTR, 29% TSS200, 26% TSS1500, and 4% 1st exon). (e) Methylation status of 152 genes associated with the 190 CpGs (37% hypermethylated,
63% hypomethylated).

1 yielded 29,722 CpGs (24,280 hyper- and 5442 hypomethylated), Tier 2 yielded 1,534 differentially methylated CpGs
(551 hyper- and 983 hypomethylated), and Tier 3 yielded 685
differentially methylated CpGs. Of the CpGs at Tier 3, 175
were hypermethylated and 510 were hypomethylated with
190 CpGs (28%) in promoter and 495 (72%) in nonpromoter
regions. The predominant location of differentially methylated CpGs in nonpromoter regions as compared to promoter
regions was also observed for CpGs at Tier 1 and Tier 2 levels
(Figure 1, Table 1).
Of the 190 promoter region CpGs, 128 were hypomethylated and 62 were hypermethylated with a functional distribution of 29% in TSS200, 26% in TSS1500, 41% in 5 UTR,
and 4% in the first exonic region. The 190 Tier 3 CpGs
mapped to 197 CpG/gene combinations, which involve 152
genes. The 152 genes include 96 (63%) hypomethylated and
56 (37%) hypermethylated (Figure 1, Table 1, and Supplementary Table 1 in Supplementary Material available online at
http://dx.doi.org/10.1155/2015/943176).

4. Discussion
Keloids share many similarities with the process of tumorigenesis. Morphologically, keloid pathogenesis is characterized

by overgrowth. Hyperplasia is a key trait and almost always is
a precursor in tumorigenesis along a malignancy continuum.
Analogies can be drawn between keloids and malignancies in
terms of their biological behavior, such as rapid proliferation
and aberrant genetic profiles, for example, the upregulation
of tumor suppressor genes such as p53 and protooncogenes
such as bcl2 [22]. Keloids thus can be described as being pseudomalignant in nature. Studies support methylated genes
not only as biomarkers of benign tumors, such as sinonasal
[26] and respiratory papillomas [27, 28], but also along a
continuum from normal to benign to malignant [29, 30]. We
hypothesized that the analogy of an epigenetic milieu might
extend to keloids as well.
Of the two types of aberrant methylation patterns present
in cancer cells [31, 32], one is gene-specific hypermethylation,
where CpG islands in the promoter regions of genes acquire
increased methylation, generally leading to reduced expression of the gene. The other is genome-wide hypomethylation, a large percentage of which occurs in repetitive DNA
elements such aslong interspersed nuclear element (LINE)
and short interspersed nuclear element (SINE, called Alu
in primates) in a variety of cancer cell lines and primary
tumor samples [31, 33]. In malignancy, aberrant gene-specific
methylation is often increased while global methylation is
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Table 1: Breakdown of 685 differentially methylated Tier 3 CpGs1 .
A: methylation status of 685 CpGs
Hypermethylated
Hypomethylated
B: 685-CpG distribution in promoter versus
nonpromoter
Promoter
Nonpromoter
C: methylation status of 190 promoter CpGs
Hypermethylated
Hypomethylated
D: 190-CpG distribution in promoter
regions
TSS200
TSS1500
5 UTR
First exon
E: methylation status of 152 genes associated
with the 190 CpGs
Hypermethylated
Hypomethylated

175 (26%)
510 (74%)

190 (28%)
495 (72%)
62 (33%)
128 (67%)

29%
26%
41%
4%

56 (37%)
96 (63%)

1

CpG (cytosine-phosphodiester bond-guanine); TSS (transcription start
site); UTR (untranslated region).

often aberrantly reduced [31, 32]. While DNA methylation is
generally associated with transcriptional silencing, the effects
of reduced global methylation or genome-wide hypomethylation can lead to chromosomal instability and an increase in
the frequency of DNA strand breaks [34].
From a genome-wide perspective, the emergence of a
more hypomethylated keloid gene promoter landscape shows
similarity with nonmalignant as well as normal developmental processes such as successful placentation [35]. A
hypomethylated keloid genomic landscape contrasts with
malignant tumor genomes, such as in breast cancer [36],
which shows more hypermethylated than hypomethylated
genes. Promoter DNA hypomethylation often results in gene
activation. The progression of scars in normal skin after
injury to a keloid pseudo tumor state may be explained by
gene silencing from hypomethylation. Our study suggests
that benign tumors adopt hypomethylation as a mechanism
for gene activation rather than gene silencing to cross thresholds into more malignant states. The latter was illustrated
for peptidase activity, shown to be hypomethylated across
cancers and required for the tumor cells to break through
the extracellular matrix and basement membrane barriers
to become invasive, and thus its predicted upregulation
via hypomethylation to promote metastasis [37]. Other
hypomethylated concepts such as epidermal and keratinocyte
development and differentiation have been linked to worse
survival prognosis and increased local invasiveness [38]. The
overall global hypomethylation status of the differentially
methylated keloid genes, despite a small discovery sample set,
is a novel contrast with cancers such as breast and head and
neck which are predominantly hypermethylated genomes.

Another observation is the predominant location of
differentially methylated CpGs in nonpromoter regions such
as gene body, 3 UTR, and intergenic as compared to promoter
regions at all three tier levels. DNA methylation at intergenic
sequences may play roles in regulating gene expression
and/or chromosome compaction during cell division and
meiosis [39]. Recent genome-wide approaches indicate that
DNA methylation can frequently occur in regions outside
of proximal promoters, including intergenic sequences [40,
41]. Evolutionarily conserved nonprotein coding regions that
were also tissue differentially methylated regions were shown
to have locations of up to 100 kb from the nearest annotated gene, consistent with potential long-range regulatory
elements such as silencers or enhancers [42].
Of the differentially methylated genes in our exploratory
methylome scan, more than a third were hypermethylated.
Several human therapeutic intervention trials are underway
to reverse deleterious hypermethylated epigenetic changes.
Examples include epigenetic therapeutic trials to treat Tcell lymphoma based on reactivation of tumor suppressor
genes [43] and similar trials to prevent colorectal cancer by
inhibiting the enzyme responsible for DNA methylation [44].
Such therapies have shown promise in halting tumor growth
by reactivation of the tumor suppressor gene or by blocking
progression of precancerous epigenetic lesions.
Epigenomic biomarkers are also becoming far more
practical than genomic biomarkers. Our group has shown
that promoter hypermethylation is amenable to polymerase
chain reaction- (PCR-) based methylation assays using whole
genomic DNA from fresh/frozen tissue and cell lines, as well
as formalin-fixed paraffin tissue DNA [26–28]. Methylation
of CpG islands may serve as a relatively simple “yes-no” signal
for the presence of tumor, and potentially the pathogenesis
of keloid tissue, when examined for under optimal assay
conditions by sensitive PCR techniques [26–29]. Additionally, aberrant promoter hypermethylation always occurs in
virtually the same location within an affected gene, allowing
a single PCR primer to be applicable to all patients for
examination of the methylation status of a specific gene
[32]. This sharply contrasts with genomic biomarkers such
as DNA mutations in genes, such as p53 or mitochondrial
genes [29], which often involve myriad different base changes
at many locations within the gene even in cancers of the
same histologic types. Classification based on promoter
methylation profiling may well be a more promising approach
than expression profiling since these DNA-based techniques
are not subject to the problems of tissue preservation and
the potential pitfalls of tissue heterogeneity. Aberrant DNA
methylation, as a stable biomarker of keloid pathogenesis
or a potential target, could be easily detected by PCR-based
methods. Furthermore, methylation profiles may represent
an early marker for the initiation, development, and/or
progression of keloid pathogenesis.
Of the differentially methylated genes in our exploratory
methylome scan, more than a third were hypermethylated.
The potential reversibility of DNA methylation patterns
may serve as a target for therapy or as a marker for
adjuvant therapy or as an adjunct to more conventional
treatments such as surgical excision and steroid injections.
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Several human therapeutic intervention trials are underway
to reverse deleterious hypermethylated epigenetic changes.
Examples include epigenetic therapeutic trials to treat Tcell lymphoma based on reactivation of tumor suppressor
genes [43] and similar trials to prevent colorectal cancer by
inhibiting the enzyme responsible for DNA methylation [44].
Such therapies have shown promise in halting tumor growth
by reactivation of the tumor suppressor gene or by blocking
progression of precancerous epigenetic lesions.
As a corollary to hypermethylation, the predominance of
hypomethylation in our keloid genome-wide scan suggesting
activated oncogene transcription rather than tumor suppressor silencing mechanisms in the promotion of tumorigenesis
opens up opportunities for drug therapies already mature in
oncogenic drug discovery pipelines. This is illustrated for Sadenosylmethionine (SAM), which serves as a major methyl
donor in biological transmethylation events. In gastric cancer
cells and colon cancer cells with hypomethylated c-myc and
h-ras promoters, treatment with SAM resulted in increased
promoter methylation and consequent downregulation of
mRNA and protein levels of c-myc and h-ras [45]. The study
found no influence on mRNA and protein levels of p16
(INK4a) with and without SAM treatment, supporting SAM
as an effective inhibitor of tumor cell growth by reversing
DNA hypomethylation.
This study provides new information about the pathogenesis of keloids highlighting a predominance of hypomethylated genomic landscapes, favoring nonpromoter regions.
Utilizing the Infinium HumanMethylation450 BeadChip kit
(Illumina, Inc., San Diego, CA), the differentially methylated
CpGs indicated 152 keloid-specific promoter region genes,
of which 63% (96) are hypomethylated as compared to 37%
(56) hypermethylated. Despite a study limitation of a small
sample size, the combination of the 450K array with a robust
three-tier data analysis approach identified a relatively large
number of statistically significant differentially methylated
genes. A strength of this study is its strategy as a discovery
approach starting from the most comprehensive currently
available human methylome platform, providing not only
new information of previously unreported genes but also
supporting studies of genes already reported in keloids as
well as some genes implicated in the pathogenesis of other
tumors. For example, ITGB7 is a gene that was identified
in this pilot study as differentially methylated in keloids
compared to normal skin. ITGB7 is a member of the integrin
family which has been found to be upregulated in keloid
tissue and keloid fibroblast [46]. Likewise, microRNA genes,
MIR199A2, MIR609, and MIR938, were also differentially
methylated in this pilot study. These genes are part of a
family of short noncoding RNA genes involved in gene
regulation. Downregulation of members of MIR7 gene has
been implicated in the overproduction of collagen in keloids
and local scleroderma [47]. Furthermore, altered expression
of MIR199A has been implicated in cervical carcinoma and
suggests a role in tumorigenesis [48].
Another limitation of the study is the anonymous nature
of the sample collection. This prevented stratification based
on demographics, treatment, or primary or recurrence status
and did not allow for patients to serve as their own control.
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Matched normal and keloid from the same individuals would
have likely allowed for less variation. Robust statistical methods employed in this study were aimed at minimizing these
variations. In the context of a pilot study, this comprehensive
scan of the keloid methylome was attempted as an initial
proof of concept to generate a knowledge base for insight
into the biological complexity of keloids from a genomewide promoter methylation perspective. It should serve as an
important step in the further exploration of methylated landscapes, including gene promoter and nonpromoter regions
as relevant areas of focus in the pathogenesis and potential
treatment of keloids. Keloids are by far the worst scars
following injury to the skin. The use of epigenetics to identify
a role for methylation in keloids may allow for a better
understanding of keloid pathogenesis and could lead us closer
to scarless surgery.

5. Conclusion
Keloid genomes overall are more hypomethylated than
hypermethylated occurring more often in nonpromoter
genomic regions. Further unraveling of the regionally methylated genomic landscape in keloids should provide a better
understanding of the contribution of the DNA methylome
to keloid pathogenesis as an additional mechanism for gene
regulation, supporting the contribution of both genetic and
epigenetic changes in keloid pathogenesis with the potential
for novel and more effective therapeutic strategies.
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